In just a few years, GLP-1s have gone from breakthrough therapies to household names, thanks to their remarkable weight loss efficacy and the unprecedented consumer demand. Since weight management is fundamentally a consumer-driven market, especially in markets where treatments are paid for out of pocket, it’s critical for pharmaceutical companies to understand the global ecosystem of weight-loss motivations, behaviors and experiences.
We used Atlas Intelligence, ZS’s proprietary AI-powered consumer intelligence platform, and built upon our U.S. findings to expand the analysis across five more key markets—the U.K., Germany, China, India and Brazil—to uncover what really drives consumer decisions per market. Our research looked at how healthcare consumers think about weight management, their motivations for managing their weight and preferences between GLP-1s and other solutions.
The data reveals striking differences across geographies. In this webinar, we unpack what these insights mean for pharma and healthcare companies globally and how they can shape smarter commercialization, marketing and partnership strategies for the years ahead.
You’ll learn:
- How consumer sentiments toward GLP-1s differ across global markets
- The impact of market-specific beliefs and attitudes on key weight-loss drivers and barriers
- Consumer behavior differences between the U.S. and major global markets
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
